Myriad Genetics has entered a partnership with GSK to provide high-grade serous ovarian cancer (HGSOC) patients access to homologous recombination deficiency (HRD) diagnostic testing.
As part of the partnership, Myriad’s MyChoice HRD Plus and MyChoice CDx Plus Tests are currently undergoing a sponsored testing program in nine countries: Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudi Arabia, Singapore, and the UAE.
The partnership aims to provide genetic insights to help clinicians develop more personalized ovarian cancer treatment plans. Clinicians can order the HRD test, a predictive and prognostic biomarker for ovarian cancer, through local pathology labs.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.